Abstract: Imidazoquinazolin-2-one compounds having platelet aggregation inhibitory activity is disclosed. These compounds have high water-solubility and reduced influences on the circulatory system and are useful for treatment and prophylaxis of intravascular thromboembolism and temporary ischemia as well as prevention of thrombus upon use of prosthetic apparatus.

Abstract: Muramyldipeptide derivatives represented by the formula: ##STR1## wherein Ala represents alanine; Acyl represents an acyl group; R.sub.1 and R.sub.2 each represents a hydrogen atom or, when taken together, may form an alkylidene group; R.sub.3 represents a hydrogen atom, an acyl group or an alkyl group; and R.sub.4 represents a hydrogen atom or an alkyl group. These compounds have excellent immunoadjuvant activity, prophylactic and therapeutic effects against microbial infections, and antitumor activity.

Abstract: Novel cephalosporin derivatives and physiologically acceptable salts thereof which are useful as antibacterial agents against gram-negative and gram-positive bacteria, and a process for preparing these compounds are disclosed.

Abstract: Mannoglucan derivatives wherein from about 2 to 51 per 100 of side chain .alpha.-D-mannopyranosyl residues of mannoglucan have been cleaved and reduced to polyhydroxy residues possess antitumor activity with reduced pyrogenecity.

Abstract: 7-Piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one having platelet aggregation inhibitory activity is disclosed. The compound has high water-solubility and reduced influences on the circulatory system.

Abstract: Pyridobenzoxazine derivatives of formula (I) ##STR1## wherein: X.sub.1 represents a hydrogen atom or a halogen atom,R.sub.1 represents a cyclic amino group which may contain additional hetero atom(s) of N,S and O and may be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, alkyl, mono- or di-alkylamino, hydroxyalkyl and aminoalkyl, and physiologically acceptable salts thereof, having antibacterial activity.

Abstract: Benzoquinolizine derivatives of formula (I) ##STR1## wherein: X.sub.1 represents a hydrogen atom or a halogen atom,R.sub.1 represents a cyclic amino group which may contain additional hetero atom(s) of N,S and O and may be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, alkyl, mono- or di-alkylamino, hydroxyalkyl and aminoalkyl, and physiologically acceptable salts thereof, having antibacterial activity.

Abstract: Pyrido[1,2,3-de][1,4]benzoxazine derivatives are described having the formula (I) ##STR1## wherein X is a halogen atom, R is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms and Z represents mono-substituted, di-substituted or cyclic-substituted amino group which may contain a hetero atom and may have a substituent such as hydroxyl, alkyl having 1 to 6 carbon atoms, amino, hydroxyalkyl having 1 to 6 carbon atoms or mono- or di-alkylamino having 1 to 6 carbon atoms in each alkyl moiety and the pharmaceutically acceptable salt thereof, having antibacterial activity.

Abstract: A method for treating and preventing bacterial infections which comprises administering a 6-O-acylmuramyl depeptide of the formula: ##STR1## wherein X represents a divalent residual group of an amino acid such as L-alanine, L-serine, L-valine, etc., Y represents a residual group of a middle to higher fatty acid having 10 to 60 carbon atoms and isoGln represents a residual group of isoglutamine, or a pharmaceutical composition containing a 6-O-acylmuramyl dipeptide of the formula(I) as an active ingredient to a patient afflicted therewith.

Abstract: Muramyldipeptide derivatives of the formula (I): ##STR1## wherein X represents an amino acid residue such as of L-alanine, L-serine, L-valine, glycine, etc., and Y represents a group ##STR2## wherein R.sub.1 represents a hydrogen atom, an alkyl group of 1 to 6 carbon atoms, a carboxamide group or a carboxyl group, n represents an integer of 1 to 6, A represents a straight or branched chain, saturated or unsaturated aliphatic hydrocarbon residue of 7 to 30 carbon atoms, and "Acyl" means an acyl group of an aliphatic carboxylic acid having 2 to 6 carbon atoms. These compounds have excellent adjuvant activity and/or prophylactic and therapeutic effects against microbial infections.

Abstract: N-phenethylacetamide compounds of the formula: ##STR1## wherein X.sub.1 represents a lower alkoxy group, X.sub.2 represents a hydrogen atom or a lower alkoxy group and R represents a phenyl group, a pyridyl group, a pyrimidinyl group or a benzoyl group, each of which may have one or more substituents selected from a halogen atom, a carbamoyl group, a lower alkoxy group, a sulfamoyl group, an amino group, a lower alkylamino group, a lower alkylthio group, a hydroxy group and a lower alkoxycarbonyl group; the parmaceutically acceptable acid addition salts and hydrates thereof; as well as the process for preparing such compounds and salts and hydrates thereof; the compounds, their salts and their hydrates having a distinct anti-peptic ulcer activity in human and animals.

Abstract: 2,3,5,8-Tetrahydrofuro- and 5,8-dihydrofuro[3,2-b]-1,8-naphthyridine compounds of the formula (I) ##STR1## wherein R.sup.1 represents an alkyl group having 1 to 6 carbon atoms and M represents a hydrogen atom, an alkali metal or an alkaline earth metal having anti-bacterial activity.

Abstract: A compound of the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 each represents a member selected from the group consisting of hydrogen and nicotinoyl, with the proviso that R.sub.1, R.sub.2 and R.sub.3 do not all simultaneously represent hydrogen, and the nontoxic acid addition salts thereof.

Abstract: A 1,2,3,5-tetrahydroimidazothienopyrimidin-2-one represented by the formula: ##STR1## wherein one of Z.sub.1, Z.sub.2 and Z.sub.3 is a sulfur atom and the remaining two of Z.sub.1, Z.sub.2 and Z.sub.3 represent CH, R.sub.1 and R.sub.2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, a chlorine atom or, when taken together R.sub.1 and R.sub.2 represent an alkylene chain of 3 to 5 carbon atoms, and R.sub.3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof, which exhibit an excellent blood platelet anti-aggregatory activity and are useful as anti-thrombotic agents.

Abstract: Compounds, which have antispasmodic effects, represented by the following formula (I) ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, an alkoxy group or, when taken together, R.sup.1 and R.sup.2 represent an alkylenedioxy group; R.sup.3 represents a hydrogen atom, an alkyl group or a cycloalkyl group; R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, an alkoxy group, an alkyl group, a halogen atom, a hydroxyl group or, when two of R.sup.4, R.sup.5 and R.sup.6 are taken together, they represent an alkylenedioxy group; and A represents a straight or branched chain alkylene group having 2 to 10 carbon atoms or an alkylene group having 2 to 10 carbon atoms and interrupted with an oxygen atom forming an ether bond therein, and the therapeutically useful acid-addition salts thereof; and a process for producing the same.

Abstract: New intermediates represented by the formula: ##STR1## wherein R.sub.1 is a lower alkyl group, a substituted lower alkyl group, an aryl group, a lower alkoxy group or an amino group and R.sub.2 is a hydrogen atom, a lower alkyl group, an aryl group, a lower acyl group, a lower alkoxycarbonyl group or a cyano group can be converted to 4'-(2-carboxyethyl)phenyl trans-4-aminomethylcyclohexanecarboxylate by selectively hydrolyzing the intermediate.

Abstract: A method for treating diabetes comprising administering a therapeutically effective amount of a 2-(2,2-disubstituted)ethylimidazoline of the general formula (I) ##STR1## wherein R is a phenyl group or a 2-pyridyl group or the pharmaceutically acceptable acid addition salts thereof, to a patient having diabetes.

Abstract: 2-SUBSTITUTED-1,3-DIAZACYCLIC COMPOUNDS OF THE FORMULA: ##STR1## wherein R.sub.1 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R.sub.2 represents a hydrogen atom, a lower alkoxycarbonyl group, an aliphatic acyl group or an aromatic acyl group, the aromatic ring of which may have one or more substituents selected from a halogen atom, a lower alkyl group, a lower alkoxy group, an acyl group and an acyloxy group; R.sub.3 represents a hydrogen atom, a lower alkyl group, a lower hydroxyalkyl group or an aralkyl group; R.sub.4 represents a hydrogen atom, a lower alkyl group or an aryl group; R.sub.6 represents a cyclohexyl group, a pyridyl group or a phenyl group which may have a substituent selected from a halogen atom, a lower alkyl group and a lower alkoxy group; A represents -N.dbd.

Abstract: An antigen consisting essentially of a catecholamine and a protein of polypeptide, wherein the protein or polypeptide is bonded to the phenyl nucleus of the catecholamine.

Abstract: Muramyldipeptide derivatives of the formula: ##STR1## wherein Y represents a mycoloyl group or a synthetic higher acyl group having total carbon number of C30-C90 and having at least a branched chain of long alkyl group on the .alpha.-position thereof,Q represents an -L-alanyl-D-isoglutamine group, a -glycyl-D-isoglutamine group or an -L-seryl-D-isoglutamine group;Salts of such derivatives; the method of preparing such derivatives and their salts; the derivatives and their salts having potent immunoadjuvant activities and antitumor activity and being applicable as the agent for the immunotherapy of cancer for humans and animals.